Mehta Adhya, Halder Sohini, Pandit Sanjay, Anuradha Subramanian
Department of Medicine, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, Delhi, India.
J Family Med Prim Care. 2023 Dec;12(12):3149-3155. doi: 10.4103/jfmpc.jfmpc_600_23. Epub 2023 Dec 21.
As the life expectancy of People Living with HIV (PLHIV) has improved with effective antiretroviral treatment (ART), they now face the challenges of accelerated ageing. Frailty is an emerging concept in the management of PLHIV and up to 28% of PLHIV are identified as frail. Frailty is a determinant of adverse clinical outcomes and is a complex clinical endpoint that has not been studied in India. This exploratory study was done to evaluate frailty and its determinants among PLHIV in India.
This was a cross-sectional study in 76 PLHIV aged 50 years or more. All the study subjects underwent a comprehensive clinical assessment. The Fried's criteria and Veterans Aging Cohort Study (VACS) Index were used to evaluate for frailty. Socio-demographic, clinical, immunological, and virological variables were assessed for their association with frailty. The study was registered under Clinical Trials Registry-India (ICMR-NIMS): REF/2019/05/025616.
The mean age of the subjects was 56.05 ± 5.8 years (range 50-76), and males constituted 81.57% (62/76) of the subjects and majority (60.53%) were underweight. On frailty assessment, 57.89% of the PLHIV were identified as prefrail/frail. Frailty had a significant association with low CD4 count ( = 0.0001) and number of comorbidities ( = 0.017) especially when comorbidities ≥2 ( = 0.04) and polypharmacy ( = 0.033). VACS index, polypharmacy, and low CD4 count ≤200 cells/mm were strong predictors of frailty. On multivariate regression analysis, CD4 count ≤200 emerged as the strongest independent predictor of frailty.
The study highlighted the high prevalence of frailty and under nutrition among aged PLHIV. The study emphasizes the need for a shift away from traditional clinical endpoints to other outcome measures for a holistic approach to PLHIV.
随着高效抗逆转录病毒治疗(ART)提高了人类免疫缺陷病毒感染者(PLHIV)的预期寿命,他们现在面临着加速衰老的挑战。衰弱是PLHIV管理中一个新出现的概念,高达28%的PLHIV被认定为衰弱。衰弱是不良临床结局的一个决定因素,是一个复杂的临床终点,在印度尚未得到研究。本探索性研究旨在评估印度PLHIV中的衰弱情况及其决定因素。
这是一项针对76名年龄在50岁及以上PLHIV的横断面研究。所有研究对象均接受了全面的临床评估。采用弗里德标准和退伍军人老龄化队列研究(VACS)指数评估衰弱情况。评估社会人口统计学、临床、免疫学和病毒学变量与衰弱的相关性。该研究已在印度临床试验注册中心(ICMR-NIMS)注册:REF/2019/05/025616。
研究对象的平均年龄为56.05±5.8岁(范围50 - 76岁),男性占研究对象的81.57%(62/76),大多数(60.53%)体重过轻。在衰弱评估中,57.89%的PLHIV被认定为衰弱前期/衰弱。衰弱与低CD4细胞计数(P = 0.0001)、合并症数量(P = 0.017)显著相关,尤其是当合并症≥2种时(P = 0.04)以及与多种药物治疗(P = 0.033)。VACS指数、多种药物治疗和低CD4细胞计数≤200个细胞/mm³是衰弱的强预测因素。在多因素回归分析中,CD4细胞计数≤200成为衰弱最强的独立预测因素。
该研究突出了老年PLHIV中衰弱和营养不良的高患病率。该研究强调需要从传统临床终点转向其他结局指标,以采取整体方法管理PLHIV。